LIM Homeodomain Regulated Genetic Pathways in Oogenesis and Ovarian Failure

LIM 同源域调控卵子发生和卵巢衰竭的遗传途径

基本信息

项目摘要

We are interested in understanding transcriptional regulation during early oogenesis, specifically the post-mitotic stages, and the transition from prenatal to postnatal ovary, when clusters of oocytes begin to form into primordial follicles. Early stages of ovarian follicle formation, beginning with the breakdown of germ cell cysts, formation of primordial follicles and transition to primary and secondary follicles, are critical in qetermining the reproductive life span and fertility. Large oocyte loses occur during these early stages of oocyte development, and unknown pro-survival factors stabilize such loss as oocytes arrest in meiotic prophase I, and primordial follicles form. Transcription of numerous germ cell specific genes, necessary and essential for follicular development and early embryogenesis, is initiated during these early stages of follicle formation. We discovered that LIM homeodomain gene, LhxB, is preferentially expressed in oocytes and critical in oocyte differentiation. In addition, multiple genes preferentially expressed in the oocyte, such as Kit are down-regulated in LhxB deficient oocytes. In Specific Aim 1, we will test the hypothesis that LhxB directly regulates numerous oocyte-specific genes including oocyte-specific transcriptional regulators. We hypothesize that LHX8 directly regulates expression of Kit, an essential regulator of primordial follicle formation. We will also perform chromatin immunoprecipitation with anti-LHX8 antibodies to determine genomic regions that LHX8 directly binds. In addition, we will study the effects of LhxB deficiency on the embryonic gonadal transcriptome and determine the onset of molecular pathology. In Specific Aim 2 we will test the hypothesis that the two LIM domains in the LHX8 protein interact with other oocytespecific transcriptional regulators as well as LIM domain binding proteins. LhxB represents the first oocyte-specific LIM homeodomain gene with critical functions during early oogenesis. Our proposed studies will provide insight into the mechanisms of LhxB action and further elucidate genetic pathways that govern oogenesis. It is likely that LhxB pathway or its co-regulators playa role in human premature ovarian failure.
我们感兴趣的是了解早期卵子发生过程中的转录调控,特别是有丝分裂后阶段,以及从产前到产后卵巢的过渡,当卵母细胞簇开始形成原始卵泡。卵泡形成的早期阶段,从生殖细胞囊肿的破裂、原始卵泡的形成和向初级和次级卵泡的过渡开始,对于确定生殖寿命和生育能力至关重要。在卵母细胞发育的这些早期阶段发生大的卵母细胞损失,并且未知的促存活因子稳定这种损失,因为卵母细胞停滞在减数分裂前期I,并且原始卵泡形成。许多生殖细胞特异性基因的转录是卵泡发育和早期胚胎发生所必需的,在卵泡形成的这些早期阶段启动。我们发现LIM同源结构域基因LhxB在卵母细胞中优先表达,并且在卵母细胞分化中起关键作用。此外,在卵母细胞中优先表达的多个基因,如Kit在LhxB缺陷的卵母细胞中下调。在具体目标1,我们将测试的假设,LhxB直接调节许多卵母细胞特异性基因,包括卵母细胞特异性转录调节因子。我们假设LHX 8直接调节Kit的表达,Kit是原始卵泡形成的重要调节因子。我们还将使用抗LHX8抗体进行染色质免疫沉淀,以确定LHX8直接结合的基因组区域。此外,我们将研究LhxB缺乏对胚胎性腺转录组的影响,并确定分子病理学的发病。在具体目标2中,我们将测试LHX 8蛋白中的两个LIM结构域与其他卵母细胞特异性转录调节因子以及LIM结构域结合蛋白相互作用的假设。LhxB是第一个在卵子发生早期具有重要功能的卵母细胞特异性LIM同源结构域基因。我们提出的研究将提供深入了解LhxB行动的机制,并进一步阐明控制卵子发生的遗传途径。LhxB通路及其协同调节因子可能在人类卵巢早衰中发挥作用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ALEKSANDAR RAJKOVIC其他文献

ALEKSANDAR RAJKOVIC的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ALEKSANDAR RAJKOVIC', 18)}}的其他基金

The Origin and Cellular Heterogeneity of Uterine Leiomyomas
子宫肌瘤的起源和细胞异质性
  • 批准号:
    10613377
  • 财政年份:
    2019
  • 资助金额:
    $ 38.33万
  • 项目类别:
The Origin and Cellular Heterogeneity of Uterine Leiomyomas
子宫肌瘤的起源和细胞异质性
  • 批准号:
    10396487
  • 财政年份:
    2019
  • 资助金额:
    $ 38.33万
  • 项目类别:
The Origin and Cellular Heterogeneity of Uterine Leiomyomas
子宫肌瘤的起源和细胞异质性
  • 批准号:
    10153843
  • 财政年份:
    2019
  • 资助金额:
    $ 38.33万
  • 项目类别:
Med12 mechanisms of uterine leiomyoma formation
子宫肌瘤形成的 Med12 机制
  • 批准号:
    9697630
  • 财政年份:
    2017
  • 资助金额:
    $ 38.33万
  • 项目类别:
Med12 mechanisms of uterine leiomyoma formation
子宫肌瘤形成的 Med12 机制
  • 批准号:
    10206208
  • 财政年份:
    2017
  • 资助金额:
    $ 38.33万
  • 项目类别:
Med12 mechanisms of uterine leiomyoma formation
子宫肌瘤形成的 Med12 机制
  • 批准号:
    9318921
  • 财政年份:
    2017
  • 资助金额:
    $ 38.33万
  • 项目类别:
Genomic integrity of the X chromosome and Ovary-Specific Autosomal Gene
X 染色体和卵巢特异性常染色体基因的基因组完整性
  • 批准号:
    8604054
  • 财政年份:
    2014
  • 资助金额:
    $ 38.33万
  • 项目类别:
Genomic integrity of the X chromosome & Ovary-Specific Autosomal Genes
X 染色体的基因组完整性
  • 批准号:
    8840981
  • 财政年份:
    2014
  • 资助金额:
    $ 38.33万
  • 项目类别:
Genomic Basis of Premature Ovarian Insufficiency
卵巢早衰的基因组基础
  • 批准号:
    8605462
  • 财政年份:
    2012
  • 资助金额:
    $ 38.33万
  • 项目类别:
Genomic Basis of Premature Ovarian Insufficiency
卵巢早衰的基因组基础
  • 批准号:
    8448606
  • 财政年份:
    2012
  • 资助金额:
    $ 38.33万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 38.33万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 38.33万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 38.33万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.33万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 38.33万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 38.33万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 38.33万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 38.33万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 38.33万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 38.33万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了